HCA

HCA

USD

HCA Healthcare Inc. Common Stock

$327.920-22.330 (-6.375%)

Цена в режиме реального времени

Healthcare
Medical Care Facilities
Соединенные Штаты

График цен

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$350.250

Максимум

$349.985

Минимум

$321.390

Объем

0.02M

Фундаментальные показатели компании

Рыночная капитализация

84.1B

Отрасль

Medical Care Facilities

Страна

United States

Статистические данные торговли

Средний объем

1.68M

Биржа

NYQ

Валюта

USD

52-недельный диапазон

Минимум $289.98Текущая $327.920Максимум $417.14

Отчет об анализе ИИ

Последнее обновление: 28 апр. 2025 г.
Сгенерировано ИИИсточник данных: Yahoo Finance, Bloomberg, SEC

HCA Healthcare Inc. Common Stock (HCA): What's Happening and What to Watch

Stock Symbol: HCA Generate Date: 2025-04-28 01:10:53

Alright, let's break down what's been going on with HCA Healthcare lately and what the tea leaves seem to be suggesting. We'll look at the recent news, how the stock price has been acting, and what some of the prediction models are saying.

Recent News Buzz: A Mixed Bag

So, what's the general feeling around HCA based on the latest headlines? It's a bit of a mixed picture, honestly.

On the positive side, the company just announced its first-quarter results for 2025. While the news title itself doesn't tell us how good or bad those results were, getting the earnings out is a key event. Plus, HCA got some nice recognition, being named one of Fortune's World's Most Admired Companies, with many of its hospitals making a top list too. That's good for reputation.

But there's also some caution popping up. A couple of analyst firms, Baird and Guggenheim, have weighed in recently. Baird actually downgraded HCA from "Outperform" to "Neutral" and lowered their price target quite a bit, from $396 down to $336. Guggenheim also started coverage with a "Neutral" rating. This tells us that while some see positives, the analyst community isn't universally gung-ho right now; some are taking a more cautious stance.

Other news floating around, like the lawsuit against DailyPay/MoneyLion or the clinical trial findings, seems less directly tied to HCA's immediate stock picture, though the clinical trial news is generally positive for the healthcare sector HCA operates in.

Putting the news together, it feels like there's underlying positive company performance and reputation, but analysts are signaling a potential slowdown or a more measured outlook compared to before.

Price Check: A Bumpy Ride Lately

Now, let's look at what the stock price itself has been doing over the last month or so. If you glance at the chart data, HCA had a pretty good run leading up to early April, even hitting highs around $349-$350.

But since then, it's pulled back noticeably. We saw a pretty sharp drop around April 4th, and then the price has been bouncing around quite a bit. The last trading day we have data for (April 25th) saw a big swing, opening high but closing significantly lower around $327.92.

Compared to those recent highs, the current price is quite a bit lower. The trend from the early April peak looks like a clear move downwards or at least sideways with a downward bias.

Interestingly, the AI prediction model we have is also pointing downwards for the very short term. It predicts negative price changes for today and the next couple of days.

Outlook & Ideas: Navigating Conflicting Signals

So, what does all this suggest? It's a bit tricky because we have some conflicting signals.

The recent price action and the AI's short-term prediction both lean cautious, suggesting the stock might face some downward pressure or volatility in the immediate future. The analyst downgrades also add to this cautious view.

However, some other data points, like certain technical indicators mentioned in the recommendation data (like MACD and DMI looking bullish, and a surge in volume on the last day which could indicate buying pressure despite the lower close), paint a more positive technical picture. The overall recommendation score is even listed as "Bullish Momentum," though the AI prediction within that same data contradicts it by saying the AI projects downward pressure.

This tells us the market view on HCA right now isn't perfectly clear-cut. There's a battle between recent negative price momentum/AI predictions and some underlying technical strength/analyst optimism (though tempered by downgrades).

Given the recent price drop and the AI's bearish short-term forecast, a cautious approach might seem reasonable right now. Watching how the stock handles the next few days could be key.

If someone were considering getting in, perhaps looking for a potential bounce, the recommendation data points to a support level around $325.18. That could be a level some traders might watch. However, it's crucial to remember the AI is predicting further drops, so relying solely on that support level without a plan is risky.

For managing risk, the recommendation data suggests a potential stop-loss around $315.38. This is a level below recent trading ranges and could be a point to consider exiting if the price continues to fall significantly.

On the flip side, if the stock does find support and starts to move up, the recommendation data lists a potential take-profit target around $334.67. This is close to where Baird set their new price target and could act as a near-term resistance level.

Putting it simply: The AI and recent trend say "watch out, might go lower." Some technicals say "there's underlying strength." This means volatility is likely. If you're thinking about this stock, have a clear plan for what you'll do if it goes down (like a stop-loss) and where you might take profits if it goes up. Patience might be the best strategy until a clearer trend emerges.

Company Context

Just a quick reminder about HCA Healthcare: they're a massive player in the healthcare world, primarily running hospitals and related facilities across the U.S. This means their business is heavily influenced by things like patient volumes, insurance dynamics, government healthcare policies, and general economic health. News about earnings, analyst views on the sector, and even broader health trends are all directly relevant to how the company performs and how investors see it.


Disclaimer: This analysis is based on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can move unexpectedly. Always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Связанные новости

Analyst Upgrades

RBC Capital Maintains Outperform on HCA Healthcare, Lowers Price Target to $376

RBC Capital analyst Ben Hendrix maintains HCA Healthcare with a Outperform and lowers the price target from $384 to $376.

Просмотреть больше
RBC Capital Maintains Outperform on HCA Healthcare, Lowers Price Target to $376
BusinessWire

HCA Healthcare Reports First Quarter 2025 Results

HCA Healthcare, Inc. (NYSE:HCA) today announced financial and operating results for the first quarter ended March 31, 2025. Key first quarter metrics (all percentage changes compare 1Q 2025 to 1Q 2024 unless otherwise

Просмотреть больше
HCA Healthcare Reports First Quarter 2025 Results
Analyst Upgrades

Baird Downgrades HCA Healthcare to Neutral, Lowers Price Target to $336

Baird analyst Michael Ha downgrades HCA Healthcare from Outperform to Neutral and lowers the price target from $396 to $336.

Просмотреть больше
Baird Downgrades HCA Healthcare to Neutral, Lowers Price Target to $336
Reuters

New York sues DailyPay and MoneyLion, alleging predatory payday lending

New York's attorney general sued DailyPay and MoneyLion on Monday, accusing the app-based financial technology companies of exploiting workers by charging excessive fees to collect paychecks more quickly, with effective interest rates above 200% and sometimes topping 750%.

Просмотреть больше
New York sues DailyPay and MoneyLion, alleging predatory payday lending
BusinessWire

Two Large Clinical Trials Find a Highly Effective Method to Select Appropriate Antibiotics for Patients Hospitalized With Abdominal or Skin and Soft Tissue Infection

Computerized alerts tailored to each patient help identify which antibiotic is best suited to treat patients hospitalized with common infections in two 92-hospital trials. Two large multi-state studies funded by the

Просмотреть больше
Two Large Clinical Trials Find a Highly Effective Method to Select Appropriate Antibiotics for Patients Hospitalized With Abdominal or Skin and Soft Tissue Infection
Analyst Upgrades

Guggenheim Initiates Coverage On HCA Healthcare with Neutral Rating

Guggenheim analyst Jason Cassorla initiates coverage on HCA Healthcare with a Neutral rating.

Прогноз ИИBeta

Рекомендация ИИ

Медвежий

Обновлено в: 28 апр. 2025 г., 16:17

МедвежийНейтральныйБычий

63.9% Уверенность

Риск и торговля

Уровень риска3/5
Средний риск
Подходит для
СтоимостьКонсервативный
Руководство по торговле

Точка входа

$324.82

Взять прибыль

$334.67

Остановить убытки

$315.32

Ключевые факторы

PDI 14.9 выше MDI 7.9 с ADX 14.6, что предполагает бычий тренд
Текущая цена очень близка к уровню поддержки ($325.18), что предполагает сильную возможность покупки
Объем торгов в 11.7 раз превышает среднее значение (17,115), что указывает на чрезвычайно сильное покупательское давление
MACD 0.8101 выше сигнальной линии 0.2789, что указывает на бычье пересечение

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.